Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 5130-5141

  Hiller, Christine ^a   Kling, Ralf C ^a   Heinemann, Frank W ^a   Meyer, Karsten ^a   Hübner, Harald ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYNYL 4 PROPYLAMINOCYCLOHEXAN 1 OL; 4 [3 (1 BUTYL 1H 1,2,3 TRIAZOL 4 YL)PROPOXY] N [4 [(6 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL] 3 METHOXYBENZAMIDE; 4 ETHYNYL 4 HYDROXYCYCLOHEXANONE; 4 ETHYNYL N PROPYLCYCLOHEX 3 ENAMINE; 8 ETHYNYL 1,4 DIOXASPIRO[4.5]DECAN 8 OL; BETA ARRESTIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; N (4 ETHYNYLCYCLOHEX 3 ENYL) 3,5 DINITRO N PROPYLBENZAMIDE; N (4 HYDROXYBUTYL)PYRAZOLO[1,5 A]PYRIDINE 2 CARBOXAMIDE; N (4 HYDROXYBUTYL)PYRAZOLO[1,5 A]PYRIDINE 3 CARBOXAMIDE; N [4 (HYDROXYBUTYL)]BIPHENYL 4 CARBOXAMIDE; N [4 [(4 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL] BIPHENYL 4 CARBOXAMIDE; N [4 [(4 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL]BENZO[B]THIOPHENE 2 CARBOXAMIDE; N [4 [(4 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL]FERROCENECARBOXAMIDE; N [4 [(4 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL]PYRAZOLO[1,5 A]PYRIDINE 2 CARBOXAMIDE; N [4 [(4 ETHYNYLCYCLOHEX 3 ENYL)PROPYLAMINO]BUTYL]PYRAZOLO[1,5 A]PYRIDINE 3 CARBOXAMIDE; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENANTIOMER; LIGAND BINDING; SIGNAL TRANSDUCTION;

ALKENES; ALKYNES; ANIMALS; DOPAMINE AGONISTS; DRUG STABILITY; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 84879596846     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400520c     Document Type: Article

References (67)

1. Neve, K. A. Functional Selectivity of G Protein-Coupled Receptor Ligands, 1 st ed.; Humana Press: Totowa, NJ, 2009; pp 25-40.
2. Wei, H.; Ahn, S.; Shenoy, S. K.; Karnik, S. S.; Hunyady, L.; Luttrell, L. M.; Lefkowitz, R. J. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10782-10787
3. Lefkowitz, R. J.; Shenoy, S. K. Transduction of receptor signals by beta-arrestins Science 2005, 308, 512-517
4. 19F-NMR Science 2012, 335, 1106-1110
5. Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F. Y.; Liu, W.; Xu, H. E.; Cherezov, V.; Roth, B. L.; Stevens, R. C. Structural features for functional selectivity at serotonin receptors Science 2013, 340, 615-619
6. Allen, J. A.; Yost, J. M.; Setola, V.; Chen, X.; Sassano, M. F.; Chen, M.; Peterson, S.; Yadav, P. N.; Huang, X. P.; Feng, B.; Jensen, N. H.; Che, X.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Caron, M. G.; Javitch, J. A.; Roth, B. L.; Jin, J. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18488-18493
7. Chen, X.; Sassano, M. F.; Zheng, L.; Setola, V.; Chen, M.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Roth, B. L.; Jin, J. Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists J. Med. Chem. 2012, 55, 7141-7153
8. Masri, B.; Salahpour, A.; Didriksen, M.; Ghisi, V.; Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Antagonism of dopamine D2 receptor/beta- arrestin 2 interaction is a common property of clinically effective antipsychotics Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13656-13661
9. Strange, P. G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects Pharmacol. Rev. 2001, 53, 119-133
10. Joyce, J. N.; Millan, M. J. Dopamine D3 receptor antagonists as therapeutic agents Drug Discovery Today 2005, 10, 917-925
11. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders Chem. Rev. 2007, 107, 274-302
12. Heidbreder, C. A.; Newman, A. H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders Ann. N.Y. Acad. Sci. 2010, 1187, 4-34
13. Beaulieu, J. M.; Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 2011, 63, 182-217
14. Lane, J. R.; Powney, B.; Wise, A.; Rees, S.; Milligan, G. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors J. Pharmacol. Exp. Ther. 2008, 325, 319-330
15. Gazi, L.; Nickolls, S. A.; Strange, P. G. Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity Br. J. Pharmacol. 2003, 138, 775-786
16. Jiang, M.; Spicher, K.; Boulay, G.; Wang, Y.; Birnbaumer, L. Most central nervous system D2 dopamine receptors are coupled to their effectors by Go Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3577-3582
17. Jiang, M.; Bajpayee, N. S. Molecular mechanisms of go signaling Neurosignals 2009, 17, 23-41
18. Liu, Y. F.; Jakobs, K. H.; Rasenick, M. M.; Albert, P. R. G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells J. Biol. Chem. 1994, 269, 13880-13886
19. Ghahremani, M. H.; Cheng, P.; Lembo, P. M.; Albert, P. R. Distinct roles for Galphai2, Galphai3, and Gbeta gamma in modulation offorskolin- or Gs-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors J. Biol. Chem. 1999, 274, 9238-9245
20. Ghahremani, M. H.; Forget, C.; Albert, P. R. Distinct roles for Galpha(i)2 and Gbetagamma in signaling to DNA synthesis and Galpha(i)3 in cellular transformation by dopamine D2S receptor activation in BALB/c 3T3 cells Mol. Cell. Biol. 2000, 20, 1497-1506
21. Quan, W.; Kim, J. H.; Albert, P. R.; Choi, H.; Kim, K. M. Roles of G protein and beta-arrestin in dopamine D2 receptor-mediated ERK activation Biochem. Biophys. Res. Commun. 2008, 377, 705-709
22. Cordeaux, Y.; Nickolls, S. A.; Flood, L. A.; Graber, S. G.; Strange, P. G. Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype J. Biol. Chem. 2001, 276, 28667-28675
23. Lober, S.; Hubner, H.; Tschammer, N.; Gmeiner, P. Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates Trends Pharmacol. Sci. 2011, 32, 148-157
24. Tschammer, N.; Bollinger, S.; Kenakin, T.; Gmeiner, P. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor Mol. Pharmacol. 2011, 79, 575-585
25. Hubner, H.; Haubmann, C.; Utz, W.; Gmeiner, P. Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D-3 subtype J. Med. Chem. 2000, 43, 756-762
26. Lenz, C.; Boeckler, F.; Hubner, H.; Gmeiner, P. Analogues of FAUC 73 revealing new insights into the structural requirements of nonaromatic dopamine D3 receptor agonists Bioorg. Med. Chem. 2004, 12, 113-117
27. Lenz, C.; Haubmann, C.; Hubner, H.; Boeckler, F.; Gmeiner, P. Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist Bioorg. Med. Chem. 2005, 13, 185-191
28. Lenz, C.; Boeckler, F.; Hubner, H.; Gmeiner, P. Fancy bioisosteres: synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands Bioorg. Med. Chem. 2005, 13, 4434-4442
29. Dorfler, M.; Tschammer, N.; Hamperl, K.; Hubner, H.; Gmeiner, P. Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies J. Med. Chem. 2008, 51, 6829-6838
30. Lange, G. L.; Gottardo, C. Facile conversion of primary and secondary alcohols to alkyl iodides Synth. Commun. 1990, 20, 1473-1479
31. Pouwer, R. H.; Schill, H.; Williams, C. M.; Bernhardt, P. V. Investigating direct access to 2-oxospiro[4.5]decanones via 6 pi-electrocyclisation Eur. J. Org. Chem. 2007, 4699-4705
32. Kuhhorn, J.; Gotz, A.; Hubner, H.; Thompson, D.; Whistler, J.; Gmeiner, P. Development of a bivalent dopamine D2 receptor agonist J. Med. Chem. 2011, 54, 7911-7919
33. Parikh, J. R.; Doering, W. v. E. Sulfur trioxide in the oxidation of alcohols by dimethyl sulfoxide J. Am. Chem. Soc. 1967, 89, 5505-5507
34. Bloomer, J. C.; Clarke, S. E.; Chenery, R. J. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole Drug Metab. Dispos. 1997, 25, 840-844
35. Ramji, J. V.; Keogh, J. P.; Blake, T. J.; Broom, C.; Chenery, R. J.; Citerone, D. R.; Lewis, V. A.; Taylor, A. C.; Yeulet, S. E. Disposition of ropinirole in animals and man Xenobiotica 1999, 29, 311-325
36. Cawello, W.; Braun, M.; Boekens, H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery Drug Metab. Dispos. 2009, 37, 2055-2060
37. Swart, P. J.; Oelen, W. E. M.; Bruins, A. P.; Tepper, P. G.; Dezeeuw, R. A. Determination of the dopamine-D2 agonist N-0923 and Its major metabolites in perfused rat livers by HPLC UV atmospheric-pressure ionization mass-spectrometry J. Anal. Toxicol. 1994, 18, 71-77
38. Hubble, J. P. Pre-clinical studies of pramipexole: clinical relevance Eur. J. Neurol. 2000, 7, 15-20
39. Koble, D. L.; Koons, J. C.; Fischer, L. J. Metabolism and disposition of the dopaminergic agonist 5-hydroxy-6-methyl-2-di-normal-propylaminotetralin in the rat Drug Metab. Dispos. 1985, 13, 305-311
40. Vyas, K. P.; Kari, P. H.; Ramjit, H. G.; Pitzenberger, S. M.; Hichens, M. Metabolism of antiparkinson agent dopazinol by rat-liver microsomes Drug Metab. Dispos. 1990, 18, 1025-1030
41. Millan, M. J.; Maiofiss, L.; Cussac, D.; Audinot, V.; Boutin, J. A.; Newman-Tancredi, A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 2002, 303, 791-804
42. Senogles, S. E. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins J. Biol. Chem. 1994, 269, 23120-23127
43. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.; Stevens, R. C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 2010, 330, 1091-1095
44. Rosenkilde, M. M.; Benned-Jensen, T.; Frimurer, T. M.; Schwartz, T. W. The minor binding pocket: a major player in 7TM receptor activation Trends Pharmacol. Sci. 2010, 31, 567-574
45. Wang, C.; Jiang, Y.; Ma, J.; Wu, H.; Wacker, D.; Katritch, V.; Han, G. W.; Liu, W.; Huang, X. P.; Vardy, E.; McCorvy, J. D.; Gao, X.; Zhou, X. E.; Melcher, K.; Zhang, C.; Bai, F.; Yang, H.; Yang, L.; Jiang, H.; Roth, B. L.; Cherezov, V.; Stevens, R. C.; Xu, H. E. Structural basis for molecular recognition at serotonin receptors Science 2013, 340, 610-614
46. Magnus, P.; Carter, P.; Elliott, J.; Lewis, R.; Harling, J.; Pitterna, T.; Bauta, W. E.; Fortt, S. Synthetic and mechanistic studies on the antitumor antibiotics esperamicin-A1 and calicheamicin-gamma-1. Synthesis of 2-letobicyclo[7.3.1] enediyne and 13-ketocyclo[7.3.1] enediyne cores mediated by eta-2 dicobalt hexacarbonyl alkyne complexes. Cycloaromatization rate studies J. Am. Chem. Soc. 1992, 114, 2544-2559
47. Geivandov, R. K.; Kovshev, E. I. New synthesis of 1,4-dihydroxybicyclo[2. 2.2]octane Zh. Org. Khim. 1979, 15, 218-219
48. Stemp, G.; Johnson, C. N. Bicyclic Amine Derivatives and Their Use as Anti-Psychotic Agents. WO9630333, 1996.
49. Sasse, B. C.; Mach, U. R.; Leppaenen, J.; Calmels, T.; Stark, H. Hybrid approach for the design of highly affine and selective dopamine D-3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands Bioorg. Med. Chem. 2007, 15, 7258-7273
50. Stark, H.; Leppanen, J. M.; Sasse, B. C.; Saur, O.; Kottke, T.; Hill, M. P. Medicaments. WO2009/056805A1, 2009.
51. Tschammer, N.; Elsner, J.; Goetz, A.; Ehrlich, K.; Schuster, S.; Ruberg, M.; Kuhhorn, J.; Thompson, D.; Whistler, J.; Hubner, H.; Gmeiner, P. Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D-3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions J. Med. Chem. 2011, 54, 2477-2491
52. Hayes, G.; Biden, T. J.; Selbie, L. A.; Shine, J. Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line Mol. Endocrinol. 1992, 6, 920-926
53. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 1990, 347, 146-151
54. Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H. H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants J. Neurochem. 1995, 65, 1157-1165
55. Bettinetti, L.; Schlotter, K.; Hubner, H.; Gmeiner, P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists J. Med. Chem. 2002, 45, 4594-4597
56. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
57. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
58. Bairoch, A.; Apweiler, R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000 Nucleic Acids Res. 2000, 28, 45-48
59. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; Gibson, T. J.; Higgins, D. G. Clustal W and Clustal X version 2.0 Bioinformatics 2007, 23, 2947-2948
60. Hall, T. A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT Nucleic Acids Symp. Ser. 1999, 41, 95-98
61. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 1993, 234, 779-815
62. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, revision B.01; Gaussian, Inc.: Wallingford, CT, 2009.
63. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31, 455-461
64. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C.L.; Wang, J.; Duke, R. E.; Luo, R.; Crowley, M.; Walker, R.C.; Zhang, W.; Merz, K. M.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Kollman, P. A. AMBER 10; University of California at San Francisco: San Francisco, CA, 2008.
65. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
66. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
67. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model J. Phys. Chem. 1993, 97, 10269-10280